Publications

Found 19 results
Filters: Author is Lahoutte, Tony  [Clear All Filters]
2016
Massa, S., N. Vikani, C. Betti, S. Ballet, S. Vanderhaegen, J. Steyaert, B. Descamps, C. Vanhove, A. Bunschoten, F. W. B. van Leeuwen, et al., "Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities.", Contrast Media Mol Imaging, vol. 11, issue 5, pp. 328-339, 2016 09.
2015
Zheng, F., N. Devoogdt, A. Sparkes, Y. Morias, C. Abels, B. Stijlemans, T. Lahoutte, S. Muyldermans, P. De Baetselier, S. Schoonooghe, et al., "Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm.", Immunobiology, vol. 220, issue 2, pp. 200-9, 2015 Feb.
2014
Evazalipour, M., M. D'huyvetter, B. Soltani Tehrani, M. Abolhassani, K. Omidfar, S. Abdoli, R. Arezumand, H. Morovvati, T. Lahoutte, S. Muyldermans, et al., "Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.", Contrast Media Mol Imaging, vol. 9, issue 3, pp. 211-20, 2014 May-Jun.
Zheng, F., S. Put, L. Bouwens, T. Lahoutte, P. Matthys, S. Muyldermans, P. De Baetselier, N. Devoogdt, G. Raes, and S. Schoonooghe, "Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis.", J Nucl Med, vol. 55, issue 5, pp. 824-9, 2014 May.
D'huyvetter, M., C. Xavier, V. Caveliers, T. Lahoutte, S. Muyldermans, and N. Devoogdt, "Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.", Expert Opin Drug Deliv, vol. 11, issue 12, pp. 1939-54, 2014 Dec.
Massa, S., C. Xavier, J. De Vos, V. Caveliers, T. Lahoutte, S. Muyldermans, and N. Devoogdt, "Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging.", Bioconjug Chem, vol. 25, issue 5, pp. 979-88, 2014 May 21.
De Vos, J., I. Mathijs, C. Xavier, S. Massa, U. Wernery, L. Bouwens, T. Lahoutte, S. Muyldermans, and N. Devoogdt, "Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.", Mol Imaging Biol, vol. 16, issue 5, pp. 690-8, 2014 Oct.
D'huyvetter, M., C. Vincke, C. Xavier, A. Aerts, N. Impens, S. Baatout, H. De Raeve, S. Muyldermans, V. Caveliers, N. Devoogdt, et al., "Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.", Theranostics, vol. 4, issue 7, pp. 708-20, 2014.
2013
De Vos, J., N. Devoogdt, T. Lahoutte, and S. Muyldermans, "Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.", Expert Opin Biol Ther, vol. 13, issue 8, pp. 1149-60, 2013 Aug.
Xavier, C., I. Vaneycken, M. D'huyvetter, J. Heemskerk, M. Keyaerts, C. Vincke, N. Devoogdt, S. Muyldermans, T. Lahoutte, and V. Caveliers, "Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.", J Nucl Med, vol. 54, issue 5, pp. 776-84, 2013 May.
2012
D'huyvetter, M., A. Aerts, C. Xavier, I. Vaneycken, N. Devoogdt, M. Gijs, N. Impens, S. Baatout, B. Ponsard, S. Muyldermans, et al., "Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.", Contrast Media Mol Imaging, vol. 7, issue 2, pp. 254-64, 2012 Mar-Apr.
Broisat, A., S. Hernot, J. Toczek, J. De Vos, L. M. Riou, S. Martin, M. Ahmadi, N. Thielens, U. Wernery, V. Caveliers, et al., "Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.", Circ Res, vol. 110, issue 7, pp. 927-37, 2012 Mar 30.
Hernot, S., S. Unnikrishnan, Z. Du, T. Shevchenko, B. Cosyns, A. Broisat, J. Toczek, V. Caveliers, S. Muyldermans, T. Lahoutte, et al., "Nanobody-coupled microbubbles as novel molecular tracer.", J Control Release, vol. 158, issue 2, pp. 346-53, 2012 Mar 10.
Hmila, I., B. Cosyns, H. Tounsi, B. Roosens, V. Caveliers, R. Ben Abderrazek, S. Boubaker, S. Muyldermans, M. El Ayeb, B. Bouhaouala-Zahar, et al., "Pre-clinical studies of toxin-specific nanobodies: evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming.", Toxicol Appl Pharmacol, vol. 264, issue 2, pp. 222-31, 2012 Oct 15.
2011
Gainkam, L. Olive Tcho, M. Keyaerts, V. Caveliers, N. Devoogdt, C. Vanhove, L. Van Grunsven, S. Muyldermans, and T. Lahoutte, "Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy.", Mol Imaging Biol, vol. 13, issue 5, pp. 940-8, 2011 Oct.
Gainkam, L. Olive Tcho, V. Caveliers, N. Devoogdt, C. Vanhove, C. Xavier, O. Boerman, S. Muyldermans, A. Bossuyt, and T. Lahoutte, "Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice.", Contrast Media Mol Imaging, vol. 6, issue 2, pp. 85-92, 2011 Mar-Apr.
Vaneycken, I., N. Devoogdt, N. Van Gassen, C. Vincke, C. Xavier, U. Wernery, S. Muyldermans, T. Lahoutte, and V. Caveliers, "Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.", FASEB J, vol. 25, issue 7, pp. 2433-46, 2011 Jul.
2010
Vaneycken, I., J. Govaert, C. Vincke, V. Caveliers, T. Lahoutte, P. De Baetselier, G. Raes, A. Bossuyt, S. Muyldermans, and N. Devoogdt, "In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT.", J Nucl Med, vol. 51, issue 7, pp. 1099-106, 2010 Jul.
De Groeve, K., N. Deschacht, C. De Koninck, V. Caveliers, T. Lahoutte, N. Devoogdt, S. Muyldermans, P. De Baetselier, and G. Raes, "Nanobodies as tools for in vivo imaging of specific immune cell types.", J Nucl Med, vol. 51, issue 5, pp. 782-9, 2010 May.